Physician profile
Jennifer A Sinclair
NPI 1295900108
$6,093.53
in general payments reported to CMS, 2019-2025
39 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $370 · 2021: $665 · 2022: $887 · 2023: $1,215 · 2024: $1,818 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,245 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.83 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,109.68 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $609.16 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $349.65 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $348.64 | 2019-2024 | |
| Celgene Corporation | $322.94 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $301.23 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $289.81 | 2019-2024 | Xifaxan, Plenvu |
| Olympus America INC. | $195.40 | 2024-2025 | Endoclot Phs, Olympus, Single Use Biopsy Valve |
| Intercept Pharmaceuticals, INC. | $144.14 | 2020-2024 | Ocaliva |
| Ucb, INC. | $142.49 | 2019-2022 | |
| Lilly USA, LLC | $120.87 | 2025 | Omvoh |
| Capsovision, INC. | $104.82 | 2025 | Capsocam Plus |
| Gilead Sciences, INC. | $99.31 | 2019-2021 | |
| Genzyme Corporation | $85.06 | 2022-2024 | |
| Braintree Laboratories, INC. | $78.72 | 2021-2024 | Sutab, Suflave |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $70.68 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $57.46 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $55.44 | 2024 | |
| Ardelyx, INC. | $52.80 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $46.89 | 2022-2024 | Dupixent |
| Axonics, INC. | $46.68 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $43.15 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.12 | 2020-2021 | |
| Shionogi INC | $40.02 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.86 | 2021 | |
| Amgen INC. | $31.22 | 2022 | |
| Endo Pharmaceuticals INC. | $28.87 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $27.38 | 2025 | Iqirvo |
| Medline Industries LP | $26.55 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.05 | 2024 | Zeposia |
| Sandoz INC. | $22.34 | 2024 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $21.28 | 2021 | |
| Enterra Medical, INC. | $20.52 | 2023 | |
| Qol Medical, LLC | $18.91 | 2021 | |
| Medtronic, INC. | $18.44 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.23 | 2021 | |
| Shield Therapeutics INC | $13.95 | 2023 | Accrufer |
| Evoke Pharma, INC. | $13.55 | 2021 | |
| Celltrion USA INC. | $13.22 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.